Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.

Mostra altre versioni (1)

OBJECTIVES: To determine long-term seroprotection after serogroup C meningococcal (MenC) vaccination at the age of 9-12 years, with or without booster vaccination at the age of 13-15 years. DESIGN: Observational cohort study; follow-on from randomised study. SETTING: Participants were recruited fro...

Descrizione completa

Dettagli Bibliografici
Autori principali:	de Whalley, P, Snape, MD, Plested, E, Thompson, B, Nuthall, E, Omar, O, Borrow, R, Pollard, A
Natura:	Journal article
Lingua:	English
Pubblicazione:	2013

Documenti analoghi

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
di: De Whalley, P, et al.
Pubblicazione: (2013)

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study
di: Snape, M, et al.
Pubblicazione: (2008)

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.
di: Snape, MD, et al.
Pubblicazione: (2008)

Will booster doses be required for serogroup B meningococcal vaccine?
di: McQuaid, F, et al.
Pubblicazione: (2014)

Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
di: Pollard, A, et al.
Pubblicazione: (2013)

Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
di: Snape, MD, et al.
Pubblicazione: (2006)

Serogroup c meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
di: Snape, M, et al.
Pubblicazione: (2006)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
di: Snape, MD, et al.
Pubblicazione: (2013)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
di: Snape, M, et al.
Pubblicazione: (2013)

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
di: Dold, C, et al.
Pubblicazione: (2023)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
di: Snape, MD, et al.
Pubblicazione: (2009)

Serogroup B meningococcal vaccines-an unfinished story.
di: Sadarangani, M, et al.
Pubblicazione: (2010)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine
di: Blanchard-Rohner, G, et al.
Pubblicazione: (2012)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
di: Blanchard-Rohner, G, et al.
Pubblicazione: (2012)

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
di: Pace, D, et al.
Pubblicazione: (2015)

HBV Seroprotection and Anamnestic Response to Booster Vaccination in Pediatric Cancer Survivors
di: Detchvijitr Suwanpakdee MD, et al.
Pubblicazione: (2021-07-01)

Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.
di: Snape, MD, et al.
Pubblicazione: (2005)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
di: Snape, MD, et al.
Pubblicazione: (2006)

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
di: Snape, MD, et al.
Pubblicazione: (2010)

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
di: Khatami, A, et al.
Pubblicazione: (2011)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
di: Lewis, S, et al.
Pubblicazione: (2009)

A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
di: Su, E, et al.
Pubblicazione: (2011)

B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
di: Perrett, K, et al.
Pubblicazione: (2012)

Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
di: Khatami, A, et al.
Pubblicazione: (2011)

Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
di: Xie, O, et al.
Pubblicazione: (2013)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine
di: O'Connor, D, et al.
Pubblicazione: (2014)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine.
di: O'Connor, D, et al.
Pubblicazione: (2014)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine
di: De Whalley, P, et al.
Pubblicazione: (2011)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
di: de Whalley, P, et al.
Pubblicazione: (2011)

Meningococcal polysaccharide-protein conjugate vaccines.
di: Snape, MD, et al.
Pubblicazione: (2005)

Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
di: Findlow, J, et al.
Pubblicazione: (2010)

Different Long-Term Duration of Seroprotection against <i>Neisseria meningitidis</i> in Adolescents and Middle-Aged Adults after a Single Meningococcal ACWY Conjugate Vaccination in The Netherlands
di: Milou Ohm, et al.
Pubblicazione: (2020-10-01)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
di: Pace, D, et al.
Pubblicazione: (2016)

Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
di: Perrett, K, et al.
Pubblicazione: (2010)

Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial
di: Perrett, K, et al.
Pubblicazione: (2010)

Impact of serogroup A meningococcal conjugate vaccine for Africa
di: James M. Stuart
Pubblicazione: (2018-05-01)

Emerging experience with meningococcal serogroup B protein vaccines
di: Daniela Toneatto, et al.
Pubblicazione: (2017-05-01)

Meningococcal serogroup B vaccines: Estimating breadth of coverage
di: Robert G. K. Donald, et al.
Pubblicazione: (2017-02-01)

Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
di: Mariëtte B van Ravenhorst, et al.
Pubblicazione: (2018-01-01)

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age
di: Snape, M, et al.
Pubblicazione: (2015)